

## HYDRATION, THERAPEUTIC, PROPHYLACTIC, AND DIAGNOSTIC INJECTIONS AND INFUSIONS

ISSUE DATE:

AUTHORITY: 32 CFR 199.4(b)(2)(v), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(ii), (e)(11)(iii), (g)(15)

---

### I. CPT<sup>1</sup> PROCEDURE CODES

96360 - 96379

### II. HCPCS PROCEDURE CODES

J3487, J3488

### III. DESCRIPTION

Intravenous (IV) hydration infusion consists of pre-packaged fluid and electrolytes, but not infusion of drugs or other substances. A therapeutic, prophylactic, or diagnostic IV infusion or injection (other than hydration) is for the administration of substances or drugs.

Policy regarding chemotherapy administration is found in [Section 16.3](#).

### IV. POLICY

A. Hydration IV infusion consistent of a pre-packaged fluid and electrolytes (e.g., normal saline, D5-1/2 normal saline +30mEq KCl/liter), but are not used to report infusion of drugs or other substances are covered.

B. Intravenous or intra-arterial push (an injection in which the health care professional who administers the substance/drug is continuously present to administer the injection and observe the patient or an infusion of 15 minutes or less) for therapy, prophylactic, or diagnosis is covered.

C. Off-label use of zoledronic acid (Zometa®) for treatment of breast cancer may be cost-shared when:

1. Patient was premenopausal at the time of diagnosis, and has stage I or II breast cancer;

---

<sup>1</sup> CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

TRICARE POLICY MANUAL 6010.54-M, AUGUST 1, 2002

CHAPTER 7, SECTION 2.8

HYDRATION, THERAPEUTIC, PROPHYLACTIC, AND DIAGNOSTIC INJECTIONS AND INFUSIONS

---

2. Patient has had surgically induced menopause (e.g., oophorectomy) or has been put temporarily into menopause (chemically induced menopause with Goserelin or similar product) prior to administration of zoledronic acid;

3. Patient has hormone receptor (Estrogen Receptor (ER) and/or Progesterone Receptor (PR)) positive disease and zoledronic acid is being used in combination with hormonal therapy (e.g., Tamoxifen, Arimedex®, Aromasin®, Femara®);

4. No concurrent adjuvant chemotherapy has been given or planned;

5. Prescriber is an oncologist or an individual highly familiar with prescribing and monitoring of oncology-related medications.

V. EFFECTIVE DATE

February 12, 2009 for off-label use of zoledronic acid (Zometa®) for treatment of breast cancer.

- END -